retatrutide and heart issues Doctor Explains The Side Effects of (Heart Issues, Cancer & More) Retatrutide Isn't a Weight Loss

Our Score: 3/5 What Is Hers

GLP-1 Orders for Overweight or Obese Patients Q1 2026 Quarterly rates per 100,000 of patients with an overweight or obese BMI receiving a prescription, dispense, or reporting starting a GLP-1 medication

So the concern is not irrational

Months 612 and beyond: Weight loss continues but typically at a slower rate as the body reaches a new equilibrium

But retatrutide is different it mimics three bodily receptors owing to weight loss: GLP-1 GIP Glucagon Existing drugs target fewer pathways: Zepbound (tirzepatide): Targets GLP-1 (glucagon-like peptide-1) + GIP (glucose-dependent insulinotropic polypeptide)

When symptoms continue despite these steps, doctors start looking for different strategies